Navigation Links
Drug Improved Survival in Mice With Cystic Fibrosis
Date:2/19/2010

Protein pathway discovery could lead to new treatments, study suggests

FRIDAY, Feb. 19 (HealthDay News) -- In the search for new treatments for cystic fibrosis, U.S. researchers have identified a defective signaling pathway that contributes to the severity of the inherited lung disease.

Cystic fibrosis causes thick, sticky mucus to build up in the lungs and digestive tract, and is one of the most common potentially lethal genetic diseases in children and young adults.

In the new study, the researchers found that correcting the defective signaling pathway for a protein called peroxisome proliferator-activated receptor-y (PPAR-y) reduced cystic fibrosis symptoms in mice.

"Cystic fibrosis results from a genetic mutation in a channel, or membrane pore, that facilitates the transport of chloride and bicarbonate electrolytes from inside the cell to the spaces outside the cell," lead investigator Dr. Gregory Harmon, of the University of California, San Diego School of Medicine, said in a news release from the school.

"Loss of the cystic fibrosis pore channel results in inflammation and mucus accumulation. It also results in dehydration of the cell surfaces that make up the lining spaces inside the lungs and other affected organs, such as the intestinal tract," he explained.

Working with cells from mice and human cell lines from cystic fibrosis patients, Harmon and his colleagues determined that multiple genes affected by PPAR-y were reduced in cystic fibrosis.

The researchers then treated mice with cystic fibrosis with the drug rosiglitazone (a drug that binds and activates PPAR-y) and found that gene expression was largely normalized and survival improved. Among the other findings:

  • Drug treatment also corrected part of the inflammatory process associated with cystic fibrosis.
  • Deleting PPAR-y in the intestine of mice worsened cystic fibrosis.
  • Activating PPAR-y can increase bicarbonate production in intestinal tissue by increasing the activity of bicarbonate-producing enzymes called carbonic anhydrases.

"For the first time, we are able to use a drug that activates bicarbonate transport without affecting chloride transport, and see improvement in the disease," Harmon said.

The findings, published in the Feb. 14 issue of Nature Medicine, may lead to new treatments for cystic fibrosis.

More information

The Cystic Fibrosis Foundation answers questions about cystic fibrosis.



-- Robert Preidt



SOURCE: University of California, San Diego Health Sciences, news release, Feb. 14, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Small to Mid-Sized Hospitals Turn to Orion Health to Implement Health IT Solutions for Improved Patient Care and Outcomes
2. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
3. Exercise Success for People Over 50: Reports of Improved Fitness, Circulation and Balance
4. Improved air quality linked to fewer pediatric ear infections
5. Chronic sinusitis patients experience improved quality of life after endoscopic sinus surgery
6. After Tough 2009, Improved Accountability and Consistent Insurance Industry Standards Key in 2010
7. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
8. IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care
9. Parent training key to improved treatment of behavior problems in children with autism
10. United Concordia Dental Redesigns Web Site To Provide Improved Access To Information
11. Parascript Announces AccuDetect 3.0 Computer Aided Detection (CAD) Algorithms With Improved Performance for CAD Vendors and Manufacturers of Mammography Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... magazine’s 2017 Training Top 125 for their industry leading training methods that engage ... recognizes USA as among the global elite in employer-sponsored training and development programs. ...
(Date:12/5/2016)... ... 2016 , ... The Avamere Family of Companies will celebrate ... Care of Puget Sound ; located at 630 S Pearl Street, Tacoma, WA ... recovering from illness or injury with intensive skilled nursing and rehabilitation services. Much ...
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... the 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and ... Talamo said, “We are honored to have Amy E. Herman present at this ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
(Date:12/5/2016)... 5, 2016  New research by the CVS ... and the U.S. Department of Health and Human ... and Response (ASPR), published online today in ... notifications encourage patients with chronic conditions to refill ... study also affirms that public-private partnerships can facilitate ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
Breaking Medicine Technology: